GLP-1 RECEPTOR, MASH, MASH TREATMENT, METABOLIC-ASSOCIATED STEATOHEPATITIS, NASH,

MASH Treatment Breakthroughs: From Supportive Care to Targeted Therapies The Turning Point: How REZDIFFRA’s Approval is Reshaping MASH Treatment The approval of Rezdiffra marks a groundbreaking advancement in the treatment of metabolic-associated steatohepatitis (MASH), redefining the therapeutic landscape. Unlike conventional approaches that c